Edgewise Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$191.4 | -$158.8 | -$114.4 | -$71.7 | -$43.2 |
| Net income | -$167.8 | -$133.8 | -$100.2 | -$67.6 | -$42.8 |
| Cash Flow Statement | |||||
| Free cash flow | -$144.1 | -$110.3 | -$97.7 | -$58.2 | -$34.2 |
Shares outstanding 108.6M · Free float 57.0%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.